Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 1,500 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jazz Pharmaceuticals Trading Down 0.1 %

JAZZ stock traded down $0.10 during trading on Wednesday, hitting $121.53. The company had a trading volume of 499,729 shares, compared to its average volume of 501,075. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a 50 day simple moving average of $122.60 and a 200-day simple moving average of $116.32. The firm has a market capitalization of $7.35 billion, a P/E ratio of 17.12, a PEG ratio of 0.90 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Creative Planning raised its position in shares of Jazz Pharmaceuticals by 21.7% in the 2nd quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock valued at $408,000 after purchasing an additional 680 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in Jazz Pharmaceuticals in the 2nd quarter worth approximately $213,000. SG Americas Securities LLC acquired a new stake in Jazz Pharmaceuticals during the third quarter valued at $752,000. GAMMA Investing LLC raised its holdings in Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 121 shares during the period. Finally, Wedmont Private Capital lifted its position in shares of Jazz Pharmaceuticals by 11.4% during the 3rd quarter. Wedmont Private Capital now owns 4,972 shares of the specialty pharmaceutical company’s stock valued at $540,000 after buying an additional 507 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. TD Cowen reduced their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, Robert W. Baird lifted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.